ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Merck and Moderna sign cancer vaccine deal

by Ryan Cross
May 13, 2018 | APPEARED IN VOLUME 96, ISSUE 20

Merck & Co. is expanding its partnership with the mRNA company Moderna Therapeutics. Merck will make a $125 million investment into the Cambridge, Mass.-based biotech and begin clinical tests of a Moderna cancer vaccine. The vaccine is designed to stimulate the immune system to spot and destroy cancer cells that have any of the four most common mutations of a protein called KRas, which is one of cancer’s toughest drug targets, found in about 30% of all tumors. Merck is eager to test the vaccine in combination with its checkpoint inhibitor immunotherapy Keytruda.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment